Results 121 to 130 of about 141,477 (341)

PrasugRel versus adjusted high-dose clopidogrel in patients with high on- clopidogrel platelet reactivity: the PECS-HPR randomized, multicenter study [PDF]

, 2015
background: Repeated loading doses (LD) of clopidogrel were shown to effectively overcome high on-clopidogrel platelet reactivity (HPR); however, comparison to potent P2Y12-inhibitors is lacking.
Aradi, Dániel
core   +1 more source

Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.

Journal of the American Medical Association (JAMA), 2016
IMPORTANCE Data are limited regarding the association between CYP2C19 genetic variants and clinical outcomes of patients with minor stroke or transient ischemic attack treated with clopidogrel.
Yilong Wang, Xingquan Zhao, Jinxi Lin, Hao Li, S. Johnston, Yi Lin, Yuesong Pan, Liping Liu, David Wang, Chunxue Wang, Xia Meng, Jianfeng Xu, Jianfeng Xu, Yongjun Wang   +13 more
semanticscholar   +1 more source

External Validation of the PRECISE‐DAPT Cancer Score in Patients With Acute Myocardial Infarction

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Aims We aimed to externally validate the PRECISE‐DAPT cancer score which showed better accuracy in predicting bleeding events in patients with cancer than the original PRECISE‐DAPT score. Methods We used data from the BleeMACS (Bleeding complications in a Multicenter registry of patients discharged after an Acute Coronary Syndrome) project. We
Mohamed Dafaalla, Francesco Costa, Evangelos Kontopantelis, Rodrigo Bagur, Mario Iannaccone, Paolo Bironzo, Sergio Raposeiras Roubí, Ovidio De Filippo, Fabrizio D'Ascenzo, Mamas A. Mamas   +9 more
wiley   +1 more source

Population pharmacokinetic‐pharmacodynamic modeling of clopidogrel for dose regimen optimization based on CYP2C19 phenotypes: A proof of concept study

CPT: Pharmacometrics & Systems Pharmacology
Clopidogrel is an antiplatelet drug used to reduce the risk of acute coronary syndrome and stroke. It is converted by CYP2C19 to its active metabolite; therefore, poor metabolizers (PMs) of CYP2C19 exhibit diminished antiplatelet effects.
Yun Seob Jung, Byung Hak Jin, Min Soo Park, Choon Ok Kim, Dongwoo Chae   +4 more
doaj   +1 more source

The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics

Cardiology Research and Practice, 2017
Dual antiplatelet therapy of aspirin and clopidogrel is pivotal for patients undergoing percutaneous coronary intervention. However, the variable platelets reactivity response to clopidogrel may lead to outcome failure and recurrence of cardiovascular ...
Arwa M. Amin, Lim Sheau Chin, Dzul Azri Mohamed Noor, Muhamad Ali SK Abdul Kader, Yuen Kah Hay, Baharudin Ibrahim   +5 more
doaj   +1 more source

Stroke following percutaneous coronary intervention : type-specific incidence, outcomes and determinants seen by the British Cardiovascular Intervention Society 2007-12 [PDF]

, 2016
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015.
Berry, Colin, British Cardiovascular Intervention Society and the National Institute for Cardiovascular Outcomes Research, Buchan, Iain, de Belder, Mark A, Keavney, Bernard, Kontopantelis, Evangelos, Kwok, Chun Shing, Ludman, Peter F, Mamas, Mamas A, Myint, Phyo K, Nolan, Jim, Zaman, Azfar   +11 more
core   +1 more source

Clopidogrel and Side Effects

Cardiology, 2001
Clopidogrel is a recently developed thrombocyte inhibitor with fewer side effects. We report 2 patients with purpura and thrombopenia, respectively, due to clopidogrel therapy. As this compound is widely used in clinical practice, the occurrence of hematological and dermal side effects should be considered.
H. Wirtz, F. Reichenberger, R. Paschke
openaire   +3 more sources

The Phenomenon of Clopidogrel High On-Treatment Platelet Reactivity in Ischemic Stroke Subjects: A Comprehensive Review

International Journal of Molecular Sciences, 2020
Clopidogrel is increasingly being used for the secondary prevention of ischemic stroke according to the updated guidelines on acute stroke management. Failure to achieve a drug response is referred to as clopidogrel resistance.
A. Wiśniewski, K. Filipska
semanticscholar   +1 more source

Navigating the Uncertainties of Antithrombotic Therapy After Transcatheter Patent Foramen Ovale Closure: A Comprehensive Review

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT The patent foramen ovale (PFO), present in 25% of the population, can cause paradoxical embolism and stroke. Transcatheter PFO closure is the gold standard for recurrent embolism with significant inter‐atrial shunting, with recent trials confirming its superiority in reducing ischemic stroke recurrence over medical therapy.
Eirini Beneki, Kyriakos Dimitriadis, Nikolaos Pyrpyris, Georgios Tzimas, Ioannis Skalidis, David Meier, Panagiotis Antiochos, Panagiotis Kostakis, Efthymia Pavlou, Francesco Perone, Georgios Tsivgoulis, Constantina Aggeli, Ole de Backer, Konstantinos Tsioufis   +13 more
wiley   +1 more source

Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults. [PDF]

, 2019
Adverse drug reactions (ADRs) contribute to hospitalization but data on its economic burden is scant. Pre-emptive pharmacogenetic (PGx) testing can potentially reduce ADRs and its associated costs.
Brunham, Liam R, Chan, Alexandre, Chan, Sze Ling, Ng, Hong Yen, Sung, Cynthia, Wee, Hwee-Lin, Winther, Michael D   +6 more
core   +1 more source